ClinicalTrials.gg
RecruitingNCT06941025MOSUpdated Nov 13, 2026

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

An observational study in Fabry Disease, Pregnancy and Pregnancy Complications, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 5 sites in 5 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..

Started
2025
with 1 other
Observational
5 of 10
3 open now
Registered
9th of 10
by date

Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 9th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The goal of this observational registry is to evaluate the safety and outcomes of pregnancy and lactation in women with Fabry disease who are exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation.

The main objectives are to:

  • Assess pregnancy outcomes, including maternal and infant health.
  • Evaluate the occurrence of congenital malformations and other neonatal outcomes.

This is a global, decentralized, single-arm, prospective and retrospective registry planned to enroll participants over a 10-year period. Eligible patients may be enrolled by their physician or may self-enroll, where permitted by local regulations. Data will be collected through a secure web-based platform, allowing patients and physicians to enter information via electronic case report forms (eCRFs).

Pregnancy and clinical outcomes will be documented throughout pregnancy and up to 12 months post-birth. Data from self-enrolled patients will be confirmed by their primary care or attending physician. This registry is observational and does not impact clinical care or treatment decisions.

Read the detailed description

This is a global, decentralized, single-arm, prospective and retrospective observational registry designed to evaluate pregnancy and infant outcomes in women with Fabry disease who have been exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation. The registry aims to assess maternal and infant safety, pregnancy outcomes, and the occurrence of congenital malformations and other neonatal conditions.

The registry will enroll patients over a 10-year period. Eligible patients may be enrolled by their physician or may self-enroll, where permitted by local regulations. Data collection will be facilitated through a secure, centralized web-based platform, where patients and physicians can enter information using electronic case report forms (eCRFs).

Enrollment \& Data Collection:

Patients can be enrolled at any time, either during pregnancy or after delivery. Depending on the timing of enrollment, data will be collected retrospectively and/or prospectively.

Pregnancy and clinical outcomes will be monitored from enrollment until the infant reaches 12 months of age.

Collected data includes maternal health, pregnancy complications, delivery outcomes, congenital malformations, and infant health parameters.

Reported congenital malformations will be classified according to established criteria (e.g., MACDP, EUROCAT) and adjudicated by an independent Scientific Advisory Committee.

The registry is observational and does not alter clinical care, physician treatment decisions, or patient management.

03

Conditions studied

  • Fabry Disease
  • Pregnancy
  • Pregnancy Complications
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant and/or breastfeeding women with Fabry disease and their infants, after exposure to at least 1 dose of pegunigalsidase alfa during pregnancy and/or during lactation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with Fabry disease who have been exposed to at least 1 dose of pegunigalsidase alfa at any time during pregnancy (defined as having received pegunigalsidase alfa within 30 days prior to the DOC and/or during pregnancy) and/or during lactation, and their infants.

    o DOC, defined as 20/7 gestational weeks, will be calculated from last menstrual period [LMP] or ultrasound

  • Patient or parent/legally authorized representative must be able to understand and provide consent through an Institutional Review Board / Independent Ethics Committee (IRB/IEC) approved Form.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with Fabry disease who were exposed to pegunigalsidase alfa during pregnancy and/or lactation

    Other: Not applicable- observational study

Interventions

  • OtherNot applicable- observational study

    Not applicable - observational study

06

What researchers measure

Primary outcomes

  1. Pregnancy outcome: Number of live births

    Time frame: at the delivery, after an average of 40 weeks of pregnancy

  2. Pregnancy outcome: Number of preterm birth

    Time frame: at delivery, prior to 37 weeks of gestation

  3. Pregnancy outcome: Number of pregnancy losses (number of spontaneous abortions , number of pregnancy terminations, number of foetal deaths or stillbirths)

    Time frame: spontaneous abortions: up to 20 weeks of pregnancy; pregnancy terminations: through the pregnancy; number of foetal deaths or stillbirths: greater than 20 weeks of pregnancy and through the pregnancy, average of 40 weeks

Secondary outcomes

  1. Number of neonates/infants with MCMs

    Time frame: through the pregnancy, an average of 40 weeks and up to 12 months of infant age

  2. Number of ectopic or molar pregnancies

    Time frame: through the pregnancy, an average of 40 weeks

  3. Number of women with obstetric and delivery complications

    Time frame: at the delivery, an average of 40 weeks of pregnancy

  4. Number of women with complications of preeclampsia or eclampsia

    Time frame: through the pregnancy, an average of 40 weeks

  5. Number of women with complications of preterm prelabour rupture of membrane

    Time frame: at delivery, prior to 37 weeks of gestation

  6. Number of neonates/infants with minor congenital malformations

    Time frame: through the pregnancy, an average of 40 weeks and up to 12 months of infant age

  7. Number of infants with developmental deficiency

    Time frame: up to 12 months of infant age

  8. Number of hospitalisations in infants

    Time frame: up to 12 months of infant age

  9. Mortality in infants, including neonatal death and infant death

    Time frame: up to 12 months of infant age

  10. Head circumference in infants (cm)

    Time frame: up to 12 months of infant age

  11. Weight in infants (kilograms)

    Time frame: up to 12 months of infant age

  12. Length in infants (cm)

    Time frame: up to 12 months of infant age

  13. Number of infants born as SGA

    Time frame: up to 12 months of infant age

  14. Number of infants with postnatal growth deficiency or FTT

    Time frame: up to 12 months of infant age

  15. Duration of breastfeeding, number of exclusively breastfeeding women and number of breastfeeding women supplemented with formula

    Time frame: up to 12 months of infant age

  16. Number of adverse events in infants exposed to pegunigalsidase alfa during breastfeeding

    Time frame: up to 12 months of infant age

07

Study locations

5 of 5 sites recruiting
  • No physical study sites - Decentralized, web-based registry
    Washington D.C., District of Columbia 20001, United States
    Recruiting
  • No physical study sites - Decentralized, web-based registry
    Berlin, Germany
    Recruiting
  • No physical study sites - Decentralized, web-based registry
    Rome, Italy
    Recruiting
  • No physical study sites - Decentralized, web-based registry
    Madrid, Spain
    Recruiting
  • No physical study sites - Decentralized, web-based registry
    London, United Kingdom
    Recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2034, 115 months after the start.

Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 115 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 23, 2025
StartActual
May 23, 2025
Primary completionEst.
Dec 2034
CompletionEst.
Dec 2034
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
No physical study sites - Decentralized, web-based registry is now Recruiting
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    No physical study sites - Decentralized, web-based registry is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06941025
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
May 23, 2025
Primary completion
Dec 2034 (estimated)
Completion
Dec 2034 (estimated)
Last update
Nov 13, 2026

Study contacts

Chiesi Clinical Trial
Contact
clinicaltrials_info@chiesi.com
+3905212791

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion